Logo image of VTYX

VENTYX BIOSCIENCES INC (VTYX) Stock Price, Quote, News and Overview

NASDAQ:VTYX - Nasdaq - US92332V1070 - Common Stock - Currency: USD

3.125  +0.1 (+3.48%)

VTYX Quote, Performance and Key Statistics

VENTYX BIOSCIENCES INC

NASDAQ:VTYX (7/23/2025, 1:55:30 PM)

3.125

+0.1 (+3.48%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High3.39
52 Week Low0.78
Market Cap222.38M
Shares71.16M
Float68.23M
Yearly DividendN/A
Dividend YieldN/A
PEN/A
Fwd PEN/A
Earnings (Next)08-07 2025-08-07/amc
IPO10-21 2021-10-21


VTYX short term performance overview.The bars show the price performance of VTYX in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 50 100 150

VTYX long term performance overview.The bars show the price performance of VTYX in the last 1, 2 and 3 years. 1 year 2 years 3 years 0 -20 -40 -60 -80

The current stock price of VTYX is 3.125 USD. In the past month the price increased by 25.83%. In the past year, price increased by 2.37%.

VENTYX BIOSCIENCES INC / VTYX Daily stock chart

VTYX Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 58.04 756.85B
JNJ JOHNSON & JOHNSON 16.84 405.21B
NVO NOVO-NORDISK A/S-SPONS ADR 19.1 312.24B
NVS NOVARTIS AG-SPONSORED ADR 13.34 228.49B
AZN ASTRAZENECA PLC-SPONS ADR 16.79 226.38B
MRK MERCK & CO. INC. 10.77 210.60B
PFE PFIZER INC 7.91 144.27B
SNY SANOFI-ADR 11.04 122.63B
BMY BRISTOL-MYERS SQUIBB CO 6.68 99.75B
GSK GSK PLC-SPON ADR 8.55 77.00B
ZTS ZOETIS INC 25.45 68.22B
TAK TAKEDA PHARMACEUTIC-SP ADR 64.11 46.06B

About VTYX

Company Profile

VTYX logo image Ventyx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing novel small molecule therapeutics for the treatment of autoimmune diseases. The company is headquartered in San Diego, California and currently employs 79 full-time employees. The company went IPO on 2021-10-21. The firm is focused on developing oral therapies for patients with autoimmune, inflammatory, and neurodegenerative diseases. Its lead portfolio of NOD-like receptor protein 3 (NLRP3) inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase II development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor in Phase II development for neurodegenerative and cardiometabolic diseases. Its inflammatory bowel disease portfolio includes tamuzimod (VTX002), an S1P1R modulator, and VTX958, a TYK2 inhibitor, both of which have completed Phase II clinical trials. Tamuzimod is a sphingosine 1 phosphate receptor (S1P1R) modulator in development for patients with moderately to severely active ulcerative colitis (UC). VTX958 is a selective allosteric tyrosine kinase type 2 (TYK2) inhibitor in Phase II development for the treatment of moderately to severely active Crohn’s disease.

Company Info

VENTYX BIOSCIENCES INC

12790 El Camino Real, Suite 200

San Diego CALIFORNIA US

Employees: 73

VTYX Company Website

VTYX Investor Relations

Phone: 18589452393

VENTYX BIOSCIENCES INC / VTYX FAQ

What is the stock price of VENTYX BIOSCIENCES INC today?

The current stock price of VTYX is 3.125 USD. The price increased by 3.48% in the last trading session.


What is the ticker symbol for VENTYX BIOSCIENCES INC stock?

The exchange symbol of VENTYX BIOSCIENCES INC is VTYX and it is listed on the Nasdaq exchange.


On which exchange is VTYX stock listed?

VTYX stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for VENTYX BIOSCIENCES INC stock?

15 analysts have analysed VTYX and the average price target is 12.24 USD. This implies a price increase of 291.68% is expected in the next year compared to the current price of 3.125. Check the VENTYX BIOSCIENCES INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is VENTYX BIOSCIENCES INC worth?

VENTYX BIOSCIENCES INC (VTYX) has a market capitalization of 222.38M USD. This makes VTYX a Micro Cap stock.


How many employees does VENTYX BIOSCIENCES INC have?

VENTYX BIOSCIENCES INC (VTYX) currently has 73 employees.


What are the support and resistance levels for VENTYX BIOSCIENCES INC (VTYX) stock?

VENTYX BIOSCIENCES INC (VTYX) has a support level at 2.94 and a resistance level at 3.17. Check the full technical report for a detailed analysis of VTYX support and resistance levels.


Should I buy VENTYX BIOSCIENCES INC (VTYX) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does VENTYX BIOSCIENCES INC (VTYX) stock pay dividends?

VTYX does not pay a dividend.


When does VENTYX BIOSCIENCES INC (VTYX) report earnings?

VENTYX BIOSCIENCES INC (VTYX) will report earnings on 2025-08-07, after the market close.


What is the Price/Earnings (PE) ratio of VENTYX BIOSCIENCES INC (VTYX)?

VENTYX BIOSCIENCES INC (VTYX) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.75).


What is the Short Interest ratio of VENTYX BIOSCIENCES INC (VTYX) stock?

The outstanding short interest for VENTYX BIOSCIENCES INC (VTYX) is 7.75% of its float. Check the ownership tab for more information on the VTYX short interest.


VTYX Technical Analysis

ChartMill assigns a technical rating of 9 / 10 to VTYX. When comparing the yearly performance of all stocks, VTYX is one of the better performing stocks in the market, outperforming 95.49% of all stocks.


Chartmill TA Rating
Chartmill Setup Rating

VTYX Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to VTYX. No worries on liquidiy or solvency for VTYX as it has an excellent financial health rating, but there are worries on the profitability.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

VTYX Financial Highlights

Over the last trailing twelve months VTYX reported a non-GAAP Earnings per Share(EPS) of -1.75. The EPS increased by 45.99% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -48.92%
ROE -53.53%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%37.1%
Sales Q2Q%N/A
EPS 1Y (TTM)45.99%
Revenue 1Y (TTM)N/A

VTYX Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to VTYX. The Buy consensus is the average rating of analysts ratings from 15 analysts.


Ownership
Inst Owners73.88%
Ins Owners4.12%
Short Float %7.75%
Short Ratio2.9
Analysts
Analysts80
Price Target12.24 (291.68%)
EPS Next Y2.78%
Revenue Next YearN/A